Reata Pharmaceuticals (NASDAQ:RETA) Stock Rating Lowered by Guggenheim

Reata Pharmaceuticals (NASDAQ:RETA – Get Free Report) was downgraded by Guggenheim from a “buy” rating to a “neutral” rating in a note issued to investors on Friday, FlyOnTheWall reports. RETA has been the subject of several other reports. Stifel Nicolaus lowered Reata Pharmaceuticals from a “buy” rating to a “hold” rating in a report on […]

Related Keywords

China ,Stifel Nicolaus ,Manmeet Singh Soni ,Michaeld Wortley ,Analyst Recommendations For Reata Pharmaceuticals ,Reata Pharmaceuticals ,Reata Pharmaceuticals Stock ,International Assets Investment Management ,China Universal Asset Management Co ,Belpointe Asset Management ,Reata Pharmaceuticals Company Profile ,Securities Exchange Commission ,Reata Pharmaceuticals Inc ,News Ratings For Reata Pharmaceuticals Daily ,Insider Activity At Reata Pharmaceuticals ,Advisor Group Holdings Inc ,Us Bancorp ,Get Free Report ,Exchange Commission ,Singh Soni ,Asset Management ,Assets Investment Management ,Universal Asset Management ,Group Holdings ,Reata Pharmaceuticals Daily ,Nasdaq Reta ,Greta ,Medical ,Downgrade ,Guggenheim ,